SLC5A2 and diabetic kidney disease: Since the expression of SGLT2 is increased in diabetic patients with persistent hyperglycemia and in patients with diabetic nephropathy, it is thought that renal glucose reabsorption by SGLT2 is a serious factor in exacerbating diabetes and that SGLT2 inhibitors are useful to prevent the development of diabetes complications [31–34].